{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:34:47Z","timestamp":1793230487352,"version":"4.5.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11046-016-0045-0","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T08:29:05Z","timestamp":1470644945000},"page":"127-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["New Antifungal Agents and New Formulations Against Dermatophytes"],"prefix":"10.1007","volume":"182","author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah G.","family":"Versteeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"key":"45_CR1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/myc.12447","volume":"59","author":"EI Nweze","year":"2016","unstructured":"Nweze EI, Eke I. Dermatophytosis in northern Africa. Mycoses. 2016;59:137\u201344.","journal-title":"Mycoses"},{"issue":"25\u20139","key":"45_CR2","first-page":"3","volume":"259","author":"AP Panthagani","year":"2015","unstructured":"Panthagani AP, Tidman MJ. Diagnosis directs treatment in fungal infections of the skin. The Practitioner. 2015;259(25\u20139):3.","journal-title":"The Practitioner"},{"key":"45_CR3","first-page":"49","volume":"15","author":"T Rosen","year":"2016","unstructured":"Rosen T. Mycological considerations in the topical treatment of superficial fungal infections. J Drugs Dermatol. 2016;15:49\u201355.","journal-title":"J Drugs Dermatol"},{"key":"45_CR4","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.14202\/vetworld.2015.1078-1082","volume":"8","author":"S Murmu","year":"2015","unstructured":"Murmu S, Debnath C, Pramanik AK, et al. Detection and characterization of zoonotic dermatophytes from dogs and cats in and around Kolkata. Vet World. 2015;8:1078\u201382.","journal-title":"Vet World"},{"key":"45_CR5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/2229-5178.178099","volume":"7","author":"AK Sahoo","year":"2016","unstructured":"Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: a comprehensive review. Indian Dermatol Online J. 2016;7:77\u201386.","journal-title":"Indian Dermatol Online J"},{"key":"45_CR6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/jid.2014.369","volume":"135","author":"SW Jaradat","year":"2015","unstructured":"Jaradat SW, Cubillos S, Krieg N, et al. Low DEFB4 copy number and high systemic hBD-2 and IL-22 levels are associated with dermatophytosis. J Invest Dermatol. 2015;135:750\u20138.","journal-title":"J Invest Dermatol"},{"key":"45_CR7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaad.2006.05.048","volume":"55","author":"DR Bickers","year":"2006","unstructured":"Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for investigative dermatology. J Am Acad Dermatol. 2006;55:490\u2013500.","journal-title":"J Am Acad Dermatol"},{"key":"45_CR8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1067\/mjd.2000.107754","volume":"43","author":"MA Ghannoum","year":"2000","unstructured":"Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"45_CR9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-4632.2009.04025.x","volume":"48","author":"A Panackal","year":"2009","unstructured":"Panackal A, Halpern E, Watson A. Cutaneous fungal infections in the United States: analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995\u20132004. Int J Dermatol. 2009;48:704\u201312.","journal-title":"Int J Dermatol"},{"key":"45_CR10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2133.1995.tb00722.x","volume":"132","author":"G Sais","year":"1995","unstructured":"Sais G, Jucgl\u00e0 A, Peyr\u00ed J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol. 1995;132:758\u201361.","journal-title":"Br J Dermatol"},{"issue":"Suppl 39","key":"45_CR11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2133.1992.tb00005.x","volume":"126","author":"DT Roberts","year":"1992","unstructured":"Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol. 1992;126(Suppl 39):23\u20137.","journal-title":"Br J Dermatol"},{"key":"45_CR12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2133.1995.tb02741.x","volume":"133","author":"H Heikkil\u00e4","year":"1995","unstructured":"Heikkil\u00e4 H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol. 1995;133:699\u2013703.","journal-title":"Br J Dermatol"},{"issue":"Suppl 4","key":"45_CR13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1439-0507.2008.01606.x","volume":"51","author":"B Havlickova","year":"2008","unstructured":"Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2\u201315.","journal-title":"Mycoses"},{"key":"45_CR14","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems [Internet]. 2013. http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm362415.htm ."},{"key":"45_CR15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-7961-2-5","volume":"2","author":"M Al Hasan","year":"2004","unstructured":"Al Hasan M, Fitzgerald SM, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: tinea pedis and its complications. Clin Mol Allergy. 2004;2:5.","journal-title":"Clin Mol Allergy"},{"key":"45_CR16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/1040841X.2013.856853","volume":"41","author":"M Ilkit","year":"2014","unstructured":"Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Crit Rev Microbiol. 2014;41:374\u201388.","journal-title":"Crit Rev Microbiol"},{"key":"45_CR17","first-page":"1138","volume":"14","author":"GLF Stein","year":"2015","unstructured":"Stein GLF, Vlahovic T, Verma A, Olayinka B, Fleischer AB. Naftifine hydrochloride gel 2%: an effective topical treatment for moccasin-type Tinea pedis. J Drugs Dermatol. 2015;14:1138\u201344.","journal-title":"J Drugs Dermatol"},{"key":"45_CR18","first-page":"312","volume":"15","author":"R Caputo","year":"2001","unstructured":"Caputo R, De Boulle K, Del Rosso J, Nowicki R. Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature. J Eur Acad Dermatol Venereol. 2001;15:312\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"45_CR19","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/clinids\/23.5.1162","volume":"23","author":"JD Semel","year":"1996","unstructured":"Semel JD, Goldin H. Association of athlete\u2019s foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis. 1996;23:1162\u20134.","journal-title":"Clin Infect Dis"},{"key":"45_CR20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11046-008-9109-0","volume":"166","author":"AK Gupta","year":"2008","unstructured":"Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166:353\u201367.","journal-title":"Mycopathologia"},{"key":"45_CR21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2230.1989.tb00908.x","volume":"14","author":"V Villars","year":"1989","unstructured":"Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil)\u2014a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol. 1989;14:124\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"45_CR22","unstructured":"Novartis Pharmaceuticals Canada Inc. Pr LAMISIL* (terbinafine hydrochloride) 250\u00a0mg tablets (expressed as base) topical cream 1% w\/w (10\u00a0mg\/g) topical spray solution 1% w\/w (10\u00a0mg\/g) Antifungal Agent [Internet]. 2016. http:\/\/webprod5.hc-sc.gc.ca\/dpd-bdpp\/info.do?code=14532&lang=eng . Accessed 14 April 2016."},{"key":"45_CR23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1365-4362.1998.00402.x","volume":"37","author":"I Tausch","year":"1998","unstructured":"Tausch I, Decroix J, Gwiezdzinski Z, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol. 1998;37:140\u20132.","journal-title":"Int J Dermatol"},{"key":"45_CR24","unstructured":"Diflucan (Fluconazole Tablets) (Fluconazole for Oral Suspension) [Internet]. 2014. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019949s060,020090s044lbl.pdf . Accessed 22 April 2016."},{"key":"45_CR25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1365-4362.1998.00541.x","volume":"37","author":"M Nozickova","year":"1998","unstructured":"Nozickova M, Koudelkova V, Kulikova Z, et al. A comparison of the efficacy of oral fluconazole, 150\u00a0mg\/week versus 50\u00a0mg\/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol. 1998;37:703\u20135.","journal-title":"Int J Dermatol"},{"key":"45_CR26","unstructured":"Terbinafine [Internet]. PubChem2016 [cited 2016 Apr 26]: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/1549008 ."},{"key":"45_CR27","unstructured":"Itraconazole [Internet]. PubChem2016 [cited 2016 Apr 26]: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/55283 ."},{"key":"45_CR28","unstructured":"Fluconazole [Internet]. PubChem2016 [cited 2016 Apr 26]: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/3365 ."},{"key":"45_CR29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/13880209.2014.914232","volume":"53","author":"Z Hu","year":"2015","unstructured":"Hu Z, Zhang J, Cheng X. Antifungal efficiency of miconazole and econazole and the interaction with transport protein: a comparative study. Pharm Biol. 2015;53:251\u201361.","journal-title":"Pharm Biol."},{"key":"45_CR30","unstructured":"Lamisil AT. Terbinafine hydrochloride cream 1% antifungal. Full prescription strength cream. [Internet]. FDA US Food Drug Adm. 2007 [cited 2016 Apr 26]: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020980s005lbl.pdf ."},{"key":"45_CR31","unstructured":"Loprox cream (cicloporix) 0.77% [Internet]. [cited 2016 Apr 26]: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018748s024,019824s023,020519s016lbl.pdf ."},{"key":"45_CR32","first-page":"17","volume":"68","author":"C Seebacher","year":"2001","unstructured":"Seebacher C, Nietsch KH, Ulbricht HM. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutis. 2001;68:17\u201322.","journal-title":"Cutis"},{"key":"45_CR33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2710.2010.01172.x","volume":"36","author":"S Weir","year":"2011","unstructured":"Weir S, Patton L, Castle K, et al. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy. J Clin Pharm Ther. 2011;36:128\u201337.","journal-title":"J Clin Pharm Ther"},{"key":"45_CR34","unstructured":"Apo-ciclopirox, ciclopirox (topical solution 8% w\/w). Product monograph. Health Can Prod Drug Data Base Apotex Inc Aug 28, Inc. 2007. http:\/\/webprod5.hc-sc.gc.ca\/dpd-bdpp\/info.do?code=78435&lang=eng . Accessed 22 April 2016."},{"key":"45_CR35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-4632.2004.02559.x","volume":"44","author":"AK Gupta","year":"2005","unstructured":"Gupta AK, Skinner AR, Cooper EA. Evaluation of the efficacy of ciclopirox 0.77% gel in the treatment of tinea pedis interdigitalis (dermatophytosis complex) in a randomized, double-blind, placebo-controlled trial. Int J Dermatol. 2005;44:590\u20133.","journal-title":"Int J Dermatol"},{"key":"45_CR36","unstructured":"Valeant INTL. ERTACZO (SERTACONAZOLE NITRATE) CREAM, 2% [Internet]. 2003 [cited 2016 Mar 10]: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/21385_Ertaczo_lbl.pdf . Accessed 22 April 2016."},{"key":"45_CR37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00003495-200969030-00009","volume":"69","author":"JD Croxtall","year":"2009","unstructured":"Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69:339\u201359.","journal-title":"Drugs."},{"key":"45_CR38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00128071-200708060-00007","volume":"8","author":"C Borelli","year":"2007","unstructured":"Borelli C, Kl\u00f6vekorn G, Ernst T-M, et al. Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis. Am J Clin Dermatol. 2007;8:371\u20138.","journal-title":"Am J Clin Dermatol"},{"key":"45_CR39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/myc.12168","volume":"57","author":"RK Scher","year":"2014","unstructured":"Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses. 2014;57:389\u201393.","journal-title":"Mycoses"},{"key":"45_CR40","first-page":"838","volume":"13","author":"M Jarratt","year":"2014","unstructured":"Jarratt M, Jones T, Adelglass J, et al. Efficacy and safety of once-daily luliconazole 1% cream in patients\u00a0\u226512\u00a0years of age with interdigital tinea pedis: a phase 3, randomized, double-blind, vehicle-controlled study. J Drugs Dermatol. 2014;13:838\u201346.","journal-title":"J Drugs Dermatol"},{"key":"45_CR41","first-page":"803","volume":"13","author":"BE Elewski","year":"2014","unstructured":"Elewski BE, Vlahovic TC. Econazole nitrate foam 1% for the treatment of tinea pedis: results from two double-blind, vehicle-controlled, phase 3 clinical trials. J Drugs Dermatol. 2014;13:803\u20138.","journal-title":"J Drugs Dermatol"},{"key":"45_CR42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2165\/00003495-199142040-00008","volume":"42","author":"JP Monk","year":"1991","unstructured":"Monk JP, Brogden RN. Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs. 1991;42:659\u201372.","journal-title":"Drugs"},{"key":"45_CR43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2133.1993.tb03172.x","volume":"129","author":"EG Evans","year":"1993","unstructured":"Evans EG, James IG, Seaman RA, Richardson MD. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole\/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol. 1993;129:437\u201342.","journal-title":"Br J Dermatol"},{"key":"45_CR44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamadermatol.2013.1721","volume":"149","author":"I Rotta","year":"2013","unstructured":"Rotta I, Ziegelmann PK, Otuki MF, et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149:341\u20139.","journal-title":"JAMA Dermatol"},{"key":"45_CR45","first-page":"CD003584","volume":"10","author":"SEM Bell-Syer","year":"2012","unstructured":"Bell-Syer SEM, Khan SM, Torgerson DJ. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev. 2012;10:CD003584.","journal-title":"Cochrane Database Syst Rev"},{"key":"45_CR46","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1365-2133.1999.02822.x","volume":"140","author":"K Merlin","year":"1999","unstructured":"Merlin K, Kilkenny M, Plunkett A, Marks R. The prevalence of common skin conditions in Australian school students: 4 Tinea pedis. Br J Dermatol. 1999;140:897\u2013901.","journal-title":"Br J Dermatol"},{"key":"45_CR47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1439-0507.2011.02121.x","volume":"55","author":"TR Hammer","year":"2012","unstructured":"Hammer TR, Mucha H, Hoefer D. Dermatophyte susceptibility varies towards antimicrobial textiles. Mycoses. 2012;55:344\u201351.","journal-title":"Mycoses"},{"key":"45_CR48","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1111\/j.1365-2648.2011.05640.x","volume":"67","author":"Y Fujiwara","year":"2011","unstructured":"Fujiwara Y, Kishida K, Terao M, et al. Beneficial effects of foot care nursing for people with diabetes mellitus: an uncontrolled before and after intervention study. J Adv Nurs. 2011;67:1952\u201362.","journal-title":"J Adv Nurs"},{"key":"45_CR49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0733-8635(03)00031-7","volume":"21","author":"AK Gupta","year":"2003","unstructured":"Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin. 2003;21:395\u2013400.","journal-title":"Dermatol Clin"},{"key":"45_CR50","doi-asserted-by":"crossref","first-page":"e4380","DOI":"10.1136\/bmj.e4380","volume":"345","author":"B Moriarty","year":"2012","unstructured":"Moriarty B, Hay R, Morris-Jones R. The diagnosis and management of tinea. BMJ. 2012;345:e4380.","journal-title":"BMJ"},{"key":"45_CR51","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bjd.13441","volume":"172","author":"EJ Zuuren van","year":"2015","unstructured":"van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. Br J Dermatol. 2015;172:616\u201341.","journal-title":"Br J Dermatol"},{"key":"45_CR52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1542\/peds.111.1.201","volume":"111","author":"SJ Alston","year":"2003","unstructured":"Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal\/corticosteroid agents. Pediatrics. 2003;111:201\u20133.","journal-title":"Pediatrics"},{"key":"45_CR53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200405040-00003","volume":"5","author":"AK Gupta","year":"2004","unstructured":"Gupta AK, Cooper EA, Ryder JE, et al. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol. 2004;5:225\u201337.","journal-title":"Am J Clin Dermatol"},{"key":"45_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12503","author":"SB Verma","year":"2016","unstructured":"Verma SB, Vasani R. Male genital dermatophytosis\u2013clinical features and the effects of the misuse of topical steroids and steroid combinations\u2014an alarming problem in India. Mycoses. 2016. doi: 10.1111\/myc.12503 .","journal-title":"Mycoses"},{"key":"45_CR55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4103\/0019-5154.119958","volume":"58","author":"S Choudhary","year":"2013","unstructured":"Choudhary S, Bisati S, Singh A, Koley S. Efficacy and safety of terbinafine hydrochloride 1% cream versus sertaconazole nitrate 2% cream in Tinea corporis and Tinea cruris: a comparative therapeutic trial. Indian J Dermatol. 2013;58:457\u201360.","journal-title":"Indian J Dermatol"},{"key":"45_CR56","first-page":"HC09","volume":"8","author":"RPM Shivamurthy","year":"2014","unstructured":"Shivamurthy RPM, Reddy SGH, Kallappa R, et al. Comparison of topical anti- fungal agents sertaconazole and clotrimazole in the treatment of tinea corporis-an observational study. J Clin Diagn Res. 2014;8:HC09\u201312.","journal-title":"J Clin Diagn Res"},{"key":"45_CR57","doi-asserted-by":"crossref","first-page":"675","DOI":"10.4103\/0250-474X.174986","volume":"77","author":"VV Pande","year":"2015","unstructured":"Pande VV, Kadnor NA, Kadam RN, Upadhye SA. Fabrication and characterization of sertaconazole nitrate microsponge as a topical drug delivery system. Indian J Pharm Sci. 2015;77:675\u201380.","journal-title":"Indian J Pharm Sci"},{"key":"45_CR58","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/10717544.2014.914601","volume":"23","author":"S Sahoo","year":"2016","unstructured":"Sahoo S, Pani NR, Sahoo SK. Effect of microemulsion in topical sertaconazole hydrogel: in vitro and in vivo study. Drug Deliv. 2016;23:338\u201345.","journal-title":"Drug Deliv"},{"key":"45_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IDR.S61998","volume":"9","author":"AK Gupta","year":"2016","unstructured":"Gupta AK, Daigle D. A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections. Infect Drug Resist. 2016;9:1\u20136.","journal-title":"Infect Drug Resist"},{"key":"45_CR60","first-page":"32","volume":"13","author":"TM Jones","year":"2014","unstructured":"Jones TM, Jarratt MT, Mendez-Moguel I, et al. A randomized, multicenter, double-blind, vehicle-controlled study evaluating the efficacy and safety of luliconazole cream 1% once daily for 7\u00a0days in patients aged\u00a0\u226512\u00a0years with tinea cruris. J Drugs Dermatol. 2014;13:32\u20138.","journal-title":"J Drugs Dermatol"},{"key":"45_CR61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/0019-5154.105284","volume":"58","author":"H Jerajani","year":"2013","unstructured":"Jerajani H, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. Indian J Dermatol. 2013;58:34\u20138.","journal-title":"Indian J Dermatol."},{"key":"45_CR62","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7897\/2230-8407.04651","volume":"4","author":"AT Selvan","year":"2013","unstructured":"Selvan AT, Girisha G, Suthakaran R. Comparative evaluation of newer topical antifungal agents in the treatment of superficial fungal infections (tinea or dermatophytic). Int Res J Pharm. 2013;4:224\u20138.","journal-title":"Int Res J Pharm"},{"key":"45_CR63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/2229-5178.131079","volume":"5","author":"SV Choudhary","year":"2014","unstructured":"Choudhary SV, Aghi T, Bisati S. Efficacy and safety of terbinafine hydrochloride 1% cream versus eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris. Indian Dermatol Online J. 2014;5:128\u201331.","journal-title":"Indian Dermatol Online J"},{"key":"45_CR64","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11046-016-0004-9","volume":"181","author":"AR Khosravi","year":"2016","unstructured":"Khosravi AR, Shokri H, Vahedi G. Factors in etiology and predisposition of adult Tinea capitis and review of published literature. Mycopathologia. 2016;181:371\u20138.","journal-title":"Mycopathologia"},{"key":"45_CR65","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjd.13196","volume":"171","author":"LC Fuller","year":"2014","unstructured":"Fuller LC, Barton RC, Mohd Mustapa MF, et al. British Association of Dermatologists\u2019 guidelines for the management of tinea capitis 2014. Br J Dermatol. 2014;171:454\u201363.","journal-title":"Br J Dermatol"},{"key":"45_CR66","unstructured":"Bortolussi R, Martin S, Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Antifungal agents for common outpatient paediatric infections. 2014. http:\/\/www.cps.ca\/documents\/position\/antifungal-agents-common-infections . Accessed 22 April 2016."},{"key":"45_CR67","doi-asserted-by":"crossref","unstructured":"Gonzalez U, Seaton T, Bergus G, Jacobson J, Martinez-Monzon C. Systemic antifungal therapy for tinea capitis in children (Review). Cochrane Database Syst Rev. 2007;CD004685.","DOI":"10.1002\/14651858.CD004685.pub2"},{"key":"45_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12501","author":"J Mashiah","year":"2016","unstructured":"Mashiah J, Kutz A, Ben Ami R, et al. Tinea capitis outbreak among paediatric refugee population, an evolving healthcare challenge. Mycoses. 2016. doi: 10.1111\/myc.12501 .","journal-title":"Mycoses"},{"key":"45_CR69","unstructured":"Bortolussi R, Martin S. Antifungal agents for common outpatient paediatric infections. Can Paediatr Soc. 2016;1\u20135. http:\/\/www.cps.ca\/documents\/position\/antifungal-agents-common-infections . Accessed 22 April 2016."},{"key":"45_CR70","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jaad.2006.08.056","volume":"55","author":"D-C Suh","year":"2006","unstructured":"Suh D-C, Friedlander SF, Raut M, et al. Tinea capitis in the United States: diagnosis, treatment, and costs. J Am Acad Dermatol. 2006;55:1111\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"45_CR71","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1468-3083.2010.03733.x","volume":"25","author":"J Boz del","year":"2011","unstructured":"del Boz J, Crespo V, Rivas-Ruiz F, de Troya M. A 30\u00a0year survey of paediatric tinea capitis in southern Spain. J Eur Acad Dermatol Venereol. 2011;25:170\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"45_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0190-9622(00)90001-X","volume":"42","author":"BE Elewski","year":"2000","unstructured":"Elewski BE. Tinea capitis: a current perspective. J Am Acad Dermatol. 2000;42:1\u201320.","journal-title":"J Am Acad Dermatol"},{"key":"45_CR73","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-4632.2004.02150.x","volume":"43","author":"RSN Brilhante","year":"2004","unstructured":"Brilhante RSN, Cordeiro RA, Rocha MFG, et al. Tinea capitis in a dermatology center in the city of Fortaleza, Brazil: the role of Trichophyton tonsurans. Int J Dermatol. 2004;43:575\u20139.","journal-title":"Int J Dermatol"},{"key":"45_CR74","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-4632.2010.04296.x","volume":"49","author":"A Mebazaa","year":"2010","unstructured":"Mebazaa A, Oumari KEL, Ghariani N, et al. Tinea capitis in adults in Tunisia. Int J Dermatol. 2010;49:513\u20136.","journal-title":"Int J Dermatol"},{"key":"45_CR75","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/1203475415578051","volume":"19","author":"RL Zur","year":"2015","unstructured":"Zur RL, Shapero J, Shapero H. Barriers to treatment of Tinea capitis in children living in the Jane Finch community of Toronto. J Cutan Med Surg. 2015;19:484\u20137.","journal-title":"J Cutan Med Surg"},{"key":"45_CR76","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1525-1470.2010.01093.x","volume":"27","author":"C Chen","year":"2010","unstructured":"Chen C, Koch LH, Dice JE, et al. A randomized, double-blind study comparing the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. Pediatr Dermatol. 2010;27:459\u201362.","journal-title":"Pediatr Dermatol"},{"key":"45_CR77","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez U, Seaton T, Bergus G, Jacobson J, Mart\u00ednez-Monz\u00f3n C. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2007;CD004685.","DOI":"10.1002\/14651858.CD004685.pub2"},{"key":"45_CR78","unstructured":"Lamisil. Package Insert: LAMISIL (terbinafine hydrochloride) Tablets, 250\u00a0mg Drugs@FDA: FDA Approved Drug Products 2012 [Internet]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020539s021lbl.pdf . Accessed 22 April 2016."},{"key":"45_CR79","unstructured":"Annex 1 19th WHO Model List of Essential Medicines [Internet]. 2015 [cited 2016 Apr 25]: http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/EML2015_8-May-15.pdf ."},{"key":"45_CR80","unstructured":"Grifulvin V. Griseofulvin Tablets, USP (Microsize) and Griseofulvin Oral Suspension, USP (Microsize) [Internet]. 2011. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/062279s022lbl.pdf . Accessed 22 April 2016."},{"key":"45_CR81","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/01.inf.0000180577.29853.a0","volume":"24","author":"SM Abdel-Rahman","year":"2005","unstructured":"Abdel-Rahman SM, Herron J, Fallon-Friedlander S, et al. Pharmacokinetics of terbinafine in young children treated for tinea capitis. Pediatr Infect Dis J. 2005;24:886\u201391.","journal-title":"Pediatr Infect Dis J"},{"key":"45_CR82","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1610-0387.2006.06133.x","volume":"4","author":"C Seebacher","year":"2006","unstructured":"Seebacher C, Abeck D, Brasch J, et al. Tinea capitis. J Dtsch Dermatol Ges. 2006;4:1085\u201391.","journal-title":"J Dtsch Dermatol Ges"},{"key":"45_CR83","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2133.1997.18141912.x","volume":"137","author":"AK Gupta","year":"1997","unstructured":"Gupta AK, Alexis ME, Raboobee N, et al. Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. Br J Dermatol. 1997;137:251\u20134.","journal-title":"Br J Dermatol"},{"key":"45_CR84","unstructured":"Pfizer. Diflucan tablets (Fluconazole) Label Information [Internet]. 2011 [cited 2012 May 30] http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019949s055,019950s059,020090s038lbl.pdf ."},{"issue":"737\u201341","key":"45_CR85","first-page":"737","volume":"11","author":"A Shemer","year":"2013","unstructured":"Shemer A, Plotnik IB, Davidovici B, et al. Treatment of tinea capitis\u2013griseofulvin versus fluconazole\u2014a comparative study. J Dtsch Dermatol Ges. 2013;11(737\u201341):737\u201342.","journal-title":"J Dtsch Dermatol Ges."},{"key":"45_CR86","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1542\/peds.69.1.81","volume":"69","author":"HB Allen","year":"1982","unstructured":"Allen HB, Honig PJ, Leyden JJ, McGinley KJ. Selenium sulfide: adjunctive therapy for tinea capitis. Pediatrics. 1982;69:81\u20133.","journal-title":"Pediatrics"},{"key":"45_CR87","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0190-9622(96)90697-0","volume":"35","author":"DL Greer","year":"1996","unstructured":"Greer DL. Treatment of tinea capitis with itraconazole. J Am Acad Dermatol. 1996;35:637\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"45_CR88","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1468-3083.2007.02173.x","volume":"21","author":"JML White","year":"2007","unstructured":"White JML, Higgins EM, Fuller LC. Screening for asymptomatic carriage of Trichophyton tonsurans in household contacts of patients with tinea capitis: results of 209 patients from South London. J Eur Acad Dermatol Venereol. 2007;21:1061\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"45_CR89","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/pde.12653","volume":"32","author":"A Shemer","year":"2015","unstructured":"Shemer A, Grunwald MH, Gupta AK, et al. Griseofulvin and fluconazole reduce transmission of Tinea capitis in schoolchildren. Pediatr Dermatol. 2015;32:696\u2013700.","journal-title":"Pediatr Dermatol"},{"key":"45_CR90","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1067\/mjd.2000.107754","volume":"43","author":"MA Ghannoum","year":"2000","unstructured":"Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"45_CR91","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40257-014-0096-2","volume":"15","author":"AK Gupta","year":"2014","unstructured":"Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15:489\u2013502.","journal-title":"Am J Clin Dermatol"},{"key":"45_CR92","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0733-8635(03)00027-5","volume":"21","author":"AK Gupta","year":"2003","unstructured":"Gupta AK, Ryder JE. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin. 2003;21:469\u201379.","journal-title":"Dermatol Clin"},{"key":"45_CR93","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40257-013-0056-2","volume":"15","author":"DC S\u00e1 de","year":"2014","unstructured":"de S\u00e1 DC, Lamas APB, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15:17\u201336.","journal-title":"Am J Clin Dermatol"},{"key":"45_CR94","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4254\/wjh.v6.i8.601","volume":"6","author":"E Raschi","year":"2014","unstructured":"Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014;6:601\u201312.","journal-title":"World J Hepatol"},{"key":"45_CR95","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/0926-9959(94)00076-C","volume":"4","author":"M Zaug","year":"1995","unstructured":"Zaug M. Amorolfine nail lacquer: clinical experience in onychomycosis. J Eur Acad Dermatol Venereol. 1995;4:S23\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"45_CR96","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1067\/mjd.2000.109071","volume":"43","author":"AK Gupta","year":"2000","unstructured":"Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43:S70\u201380.","journal-title":"J Am Acad Dermatol"},{"key":"45_CR97","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","volume":"68","author":"BE Elewski","year":"2013","unstructured":"Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"45_CR98","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2015.04.010","volume":"73","author":"BE Elewski","year":"2015","unstructured":"Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"45_CR99","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11046-010-9347-9","volume":"171","author":"TR Hammer","year":"2011","unstructured":"Hammer TR, Mucha H, Hoefer D. Infection risk by dermatophytes during storage and after domestic laundry and their temperature-dependent inactivation. Mycopathologia. 2011;171:43\u20139.","journal-title":"Mycopathologia"},{"key":"45_CR100","first-page":"279","volume":"15","author":"AK Gupta","year":"2016","unstructured":"Gupta AK, Elewski BE, Rosen T, et al. Onychomycosis: strategies to minimize recurrence. J Drugs Dermatol. 2016;15:279\u201382.","journal-title":"J Drugs Dermatol"},{"key":"45_CR101","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1468-3083.2009.03547.x","volume":"24","author":"B Sigurgeirsson","year":"2010","unstructured":"Sigurgeirsson B, Olafsson J, Steinsson J, Kerrouche N, Sidou F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol. 2010;24:910\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"45_CR102","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000433473","volume":"1","author":"AK Gupta","year":"2015","unstructured":"Gupta AK, Daigle D, Foley KA. Network meta-analysis of onychomycosis treatments. Skin Appendage Disord. 2015;1:74\u201381.","journal-title":"Skin Appendage Disord"},{"key":"45_CR103","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1468-3083.2012.04584.x","volume":"27","author":"AK Gupta","year":"2013","unstructured":"Gupta AK, Paquet M, Simpson F, Tavakkol A. Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol. 2013;27:267\u201372.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"45_CR104","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2011.02.038","volume":"66","author":"AK Gupta","year":"2012","unstructured":"Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66:494\u2013502.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 56","key":"45_CR105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.1999.00008.x","volume":"141","author":"B Sigurgeirsson","year":"1999","unstructured":"Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil versus itraconazole in onychomycosis. Br J Dermatol. 1999;141(Suppl 56):5\u201314.","journal-title":"Br J Dermatol"},{"key":"45_CR106","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000441569","volume":"1","author":"M Iorizzo","year":"2016","unstructured":"Iorizzo M, Hartmane I, Derveniece A, Mikazans I. Ciclopirox 8% HPCH nail lacquer in the treatment of mild-to-moderate onychomycosis: a randomized, double-blind amorolfine controlled study using a blinded evaluator. Skin Appendage Disord. 2016;1:134\u201340.","journal-title":"Skin Appendage Disord"},{"key":"45_CR107","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1468-3083.2009.03164.x","volume":"23","author":"R Baran","year":"2009","unstructured":"Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol. 2009;23:773\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"45_CR108","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1517\/14656566.2016.1146687","volume":"17","author":"A Gupta","year":"2016","unstructured":"Gupta A, Cernea M. How effective is efinaconazole in the management of onychomycosis? Expert Opin Pharmacother. 2016;17:611\u20138.","journal-title":"Expert Opin Pharmacother"},{"key":"45_CR109","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1586\/14787210.2014.915738","volume":"12","author":"AK Gupta","year":"2014","unstructured":"Gupta AK, Daigle D. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults. Expert Rev Anti Infect Ther. 2014;12:735\u201342.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"45_CR110","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1517\/13543784.2016.1142529","volume":"25","author":"AK Gupta","year":"2016","unstructured":"Gupta AK, Studholme C. Novel investigational therapies for onychomycosis: an update. Expert Opin Investig Drugs. 2016;25:297\u2013305.","journal-title":"Expert Opin Investig Drugs"},{"key":"45_CR111","first-page":"1388","volume":"13","author":"M Sakamoto","year":"2014","unstructured":"Sakamoto M, Sugimoto N, Kawabata H, et al. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. J Drugs Dermatol. 2014;13:1388\u201392.","journal-title":"J Drugs Dermatol"},{"key":"45_CR112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/13543784.16.2.157","volume":"16","author":"MR Alley","year":"2007","unstructured":"Alley MR, Baker SJ, Beutner KR, Plattner J. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs. 2007;16:157\u201367.","journal-title":"Expert Opin Investig Drugs"},{"key":"45_CR113","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2133.149.s65.2.x","volume":"149","author":"JH Olafsson","year":"2003","unstructured":"Olafsson JH. Combination therapy for onychomycosis. Br J Dermatol. 2003;149:15\u20138.","journal-title":"Br J Dermatol"},{"key":"45_CR114","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/09546630500420183","volume":"16","author":"S Avner","year":"2005","unstructured":"Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatol Treat. 2005;16:327\u201330.","journal-title":"J Dermatol Treat."},{"key":"45_CR115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2133.2007.07974.x","volume":"157","author":"R Baran","year":"2007","unstructured":"Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol. 2007;157:149\u201357.","journal-title":"Br J Dermatol"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-016-0045-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11046-016-0045-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-016-0045-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-016-0045-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T10:19:41Z","timestamp":1657016381000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11046-016-0045-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":115,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1007\/s11046-016-0045-0","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]}}}